Antengene (6996) investor relations material

Executive summary

• Achieved first-ever profitability in H1 2026, driven by strategic licensing partnerships and robust pipeline advancement, with revenue surging to RMB513.1 million mainly from deals for ATG-201 and ATG-106.

• Major licensing deals with UCB and K2 Therapeutics for next-generation TCE programs contributed significant upfront and milestone payments.

• Net profit reached RMB216.3 million, reversing a prior loss, supported by upfront payments and strong R&D innovation.

• Commercial asset XPOVIO® expanded reimbursement in South Korea and maintained approvals in 10 APAC markets.

• Pipeline advanced with new clinical and preclinical programs, including pivotal Phase III for ATG-022 and IND approval for ATG-201.

Financial highlights

• H1 2026 adjusted profit reached RMB284.7 million, with total revenue at RMB513 million, mainly from licensing revenue.

• Gross profit increased to RMB480.4 million from RMB42.9 million year-over-year.

• Cash and bank balances stood at RMB765 million as of June 30, 2026, with additional inflows of RMB195 million in July and US$20 million in near-term milestone payments.

• R&D costs increased 53.8% year-over-year to RMB122.9 million, reflecting pipeline investment.

• Selling and distribution expenses decreased 4.7% and administrative expenses decreased 8.6% year-over-year.

Outlook and guidance

• Multiple revenue streams from new and existing business development deals expected to sustain profitability beyond 2026.

• Focus remains on accelerating development of high-potential clinical assets, especially ATG-022 and ATG-037.

• Continued expansion of XPOVIO® market penetration and reimbursement access in APAC.

• No interim dividend declared for H1 2026.

• Continued investment in next-generation platforms and pipeline to drive future growth.